Polypharmacology report

Abreviations used here:

  • kA:The number of active compounds known to target the pattern
  • KA:The total number of active compounds(IC50 < 10-6)
  • kB:The number of inactive compounds known to target the pattern
  • KB:The total number of inactive compounds(IC50 >10-6)
  • Odds Ratio: (kA/kB) / ( (KA-kA) / (KB - kB) )

Individual statistics for ATXN2 in the assay 686971:

  • kA: 1236
  • KA: 7342
  • kB: 2114
  • KB: 227332
  • Odds Ratio: 21.6

Table 1. Poly-pharmacological protein patterns (with ATXN2) enriched among Active molecules

# Target Duplet P-value
FDR adjusted
Odds Ratio kA KA kB KB Polypharmacology triplets View
Compounds
details
View Pattern Profile
1 ATXN2 and IDH1 0. 114.5 868 7342 266 227332 Polypharmacology Molecules Target Profile
2 ATXN2 and EPAS1 0. 79.3 524 7342 220 227332 Polypharmacology Molecules Target Profile
3 ATXN2 and CFTR 0. 72.0 563 7342 262 227332 Polypharmacology Molecules Target Profile
4 ATXN2 and TNFRSF10B 0. 69.8 411 7342 193 227332 Polypharmacology Molecules Target Profile
5 ATXN2 and HIF1A 0. 65.3 290 7342 143 227332 Polypharmacology Molecules Target Profile
6 ATXN2 and PAX8 0. 64.5 355 7342 179 227332 Polypharmacology Molecules Target Profile
7 ATXN2 and NOD1 0. 63.3 285 7342 145 227332 Polypharmacology Molecules Target Profile
8 ATXN2 and HNF4A 3.49e-278 57.3 259 7342 145 227332 Polypharmacology Molecules Target Profile
9 ATXN2 and MITF 0. 54.6 612 7342 378 227332 Polypharmacology Molecules Target Profile
10 ATXN2 and NFE2L2 4.75e-288 47.1 281 7342 192 227332 Polypharmacology Molecules Target Profile
11 ATXN2 and DRD3 0. 46.8 425 7342 298 227332 Polypharmacology Molecules Target Profile
12 ATXN2 and SMAD3 0. 44.1 490 7342 368 227332 Polypharmacology Molecules Target Profile
13 ATXN2 and RORC 3.16e-13 310.1 10 7342 1 227332 Polypharmacology Molecules Target Profile
14 ATXN2 and NCOA2 2.22e-193 203.3 148 7342 23 227332 Polypharmacology Molecules Target Profile
15 ATXN2 and RAD51 1.63e-07 185.9 6 7342 1 227332 Polypharmacology Molecules Target Profile
16 ATXN2 and NCOA1 1.39e-127 165.2 100 7342 19 227332 Polypharmacology Molecules Target Profile
17 ATXN2 and NCOA3 2.31e-228 162.3 179 7342 35 227332 Polypharmacology Molecules Target Profile
18 ATXN2 and GALK1 8.10e-19 155.1 15 7342 3 227332 Polypharmacology Molecules Target Profile
19 ATXN2 and HSPA1A 5.24e-35 145.0 28 7342 6 227332 Polypharmacology Molecules Target Profile
20 ATXN2 and S1PR3 1.33e-33 139.8 27 7342 6 227332 Polypharmacology Molecules Target Profile
21 ATXN2 and KLF5 4.71e-42 132.2 34 7342 8 227332 Polypharmacology Molecules Target Profile
22 ATXN2 and SELE 7.47e-57 130.3 46 7342 11 227332 Polypharmacology Molecules Target Profile
23 ATXN2 and NFKB1 2.50e-34 124.3 28 7342 7 227332 Polypharmacology Molecules Target Profile
24 ATXN2 and LHCGR 1.76e-24 124.2 20 7342 5 227332 Polypharmacology Molecules Target Profile
25 ATXN2 and HSPB1 1.10e-09 124.0 8 7342 2 227332 Polypharmacology Molecules Target Profile
26 ATXN2 and PTPN7 1.10e-09 124.0 8 7342 2 227332 Polypharmacology Molecules Target Profile
27 ATXN2 and ROCK2 0.000101 123.9 4 7342 1 227332 Polypharmacology Molecules Target Profile
28 ATXN2 and TNFSF10 4.73e-66 120.3 54 7342 14 227332 Polypharmacology Molecules Target Profile
29 ATXN2 and NR5A2 2.02e-238 117.0 195 7342 53 227332 Polypharmacology Molecules Target Profile
30 ATXN2 and PTPN22 2.66e-08 108.5 7 7342 2 227332 Polypharmacology Molecules Target Profile
31 ATXN2 and PRNP 2.37e-148 107.6 123 7342 36 227332 Polypharmacology Molecules Target Profile
32 ATXN2 and S1PR4 3.56e-144 104.9 120 7342 36 227332 Polypharmacology Molecules Target Profile
33 ATXN2 and TLR9 1.50e-126 100.9 106 7342 33 227332 Polypharmacology Molecules Target Profile
34 ATXN2 and GPR35 2.07e-15 100.8 13 7342 4 227332 Polypharmacology Molecules Target Profile
35 ATXN2 and S1PR1 1.96e-102 99.8 86 7342 27 227332 Polypharmacology Molecules Target Profile
36 ATXN2 and NR1H4 1.71e-10 93.0 9 7342 3 227332 Polypharmacology Molecules Target Profile
37 ATXN2 and KDM4A 6.17e-07 93.0 6 7342 2 227332 Polypharmacology Molecules Target Profile
38 ATXN2 and GALR3 7.38e-73 92.2 62 7342 21 227332 Polypharmacology Molecules Target Profile
39 ATXN2 and TLR4 7.78e-27 89.3 23 7342 8 227332 Polypharmacology Molecules Target Profile
40 ATXN2 and NR5A1 5.23e-221 88.3 189 7342 68 227332 Polypharmacology Molecules Target Profile
41 ATXN2 and NR2F2 2.75e-210 87.9 180 7342 65 227332 Polypharmacology Molecules Target Profile
42 ATXN2 and XBP1 2.64e-60 85.3 52 7342 19 227332 Polypharmacology Molecules Target Profile
43 ATXN2 and GALR2 2.99e-113 83.1 98 7342 37 227332 Polypharmacology Molecules Target Profile
44 ATXN2 and CYP19A1 1.18e-27 82.8 24 7342 9 227332 Polypharmacology Molecules Target Profile
45 ATXN2 and STAT1 3.85e-106 82.4 92 7342 35 227332 Polypharmacology Molecules Target Profile
46 ATXN2 and TDP2 3.12e-56 80.4 49 7342 19 227332 Polypharmacology Molecules Target Profile
47 ATXN2 and PADI4 4.04e-79 79.9 69 7342 27 227332 Polypharmacology Molecules Target Profile
48 ATXN2 and RORA 5.16e-32 79.1 28 7342 11 227332 Polypharmacology Molecules Target Profile
49 ATXN2 and NR2E3 2.67e-176 78.5 154 7342 62 227332 Polypharmacology Molecules Target Profile
50 ATXN2 and S1PR2 6.57e-40 77.8 35 7342 14 227332 Polypharmacology Molecules Target Profile
51 ATXN2 and ABCB6 3.39e-34 77.7 30 7342 12 227332 Polypharmacology Molecules Target Profile
52 ATXN2 and TLR3 2.45e-11 77.5 10 7342 4 227332 Polypharmacology Molecules Target Profile
53 ATXN2 and PAFAH1B3 2.14e-90 73.6 80 7342 34 227332 Polypharmacology Molecules Target Profile
54 ATXN2 and JAK2 4.57e-221 72.5 196 7342 86 227332 Polypharmacology Molecules Target Profile
55 ATXN2 and P4HB 1.27e-23 72.5 21 7342 9 227332 Polypharmacology Molecules Target Profile
56 ATXN2 and APP 3.09e-173 71.6 154 7342 68 227332 Polypharmacology Molecules Target Profile
57 ATXN2 and PPARD 5.28e-10 69.8 9 7342 4 227332 Polypharmacology Molecules Target Profile
58 ATXN2 and NR3C1 3.35e-12 68.2 11 7342 5 227332 Polypharmacology Molecules Target Profile
59 ATXN2 and HKDC1 1.11e-108 66.8 98 7342 46 227332 Polypharmacology Molecules Target Profile
60 ATXN2 and TNF 1.86e-203 65.6 184 7342 89 227332 Polypharmacology Molecules Target Profile
61 ATXN2 and STAT3 4.11e-87 65.1 79 7342 38 227332 Polypharmacology Molecules Target Profile
62 ATXN2 and MBD2 2.87e-36 64.1 33 7342 16 227332 Polypharmacology Molecules Target Profile
63 ATXN2 and NOD2 3.16e-212 63.9 193 7342 96 227332 Polypharmacology Molecules Target Profile
64 ATXN2 and HTR1E 1.66e-41 62.2 38 7342 19 227332 Polypharmacology Molecules Target Profile
65 ATXN2 and TSHR 3.77e-108 62.1 99 7342 50 227332 Polypharmacology Molecules Target Profile
66 ATXN2 and IL8 1.10e-08 62.0 8 7342 4 227332 Polypharmacology Molecules Target Profile
67 ATXN2 and TRPV1 1.75e-06 62.0 6 7342 3 227332 Polypharmacology Molecules Target Profile
68 ATXN2 and ABCG2 1.75e-06 62.0 6 7342 3 227332 Polypharmacology Molecules Target Profile
69 ATXN2 and VCP 1.45e-44 60.8 41 7342 21 227332 Polypharmacology Molecules Target Profile
70 ATXN2 and PLIN1 6.81e-25 59.5 23 7342 12 227332 Polypharmacology Molecules Target Profile
71 ATXN2 and GPR183 1.12e-140 59.4 130 7342 69 227332 Polypharmacology Molecules Target Profile
72 ATXN2 and BLM 1.94e-59 59.2 55 7342 29 227332 Polypharmacology Molecules Target Profile
73 ATXN2 and ERAP1 2.46e-18 58.6 17 7342 9 227332 Polypharmacology Molecules Target Profile
74 ATXN2 and AGTR1 2.56e-32 58.3 30 7342 16 227332 Polypharmacology Molecules Target Profile
75 ATXN2 and HTR1A 6.17e-42 57.8 39 7342 21 227332 Polypharmacology Molecules Target Profile
76 ATXN2 and AR 9.02e-26 57.3 24 7342 13 227332 Polypharmacology Molecules Target Profile
77 ATXN2 and POLI 7.55e-162 56.8 151 7342 84 227332 Polypharmacology Molecules Target Profile
78 ATXN2 and MCOLN3 3.22e-19 55.9 18 7342 10 227332 Polypharmacology Molecules Target Profile
79 ATXN2 and MPHOSPH8 1.40e-09 55.8 9 7342 5 227332 Polypharmacology Molecules Target Profile
80 ATXN2 and MTOR 4.90e-17 55.2 16 7342 9 227332 Polypharmacology Molecules Target Profile
81 ATXN2 and CTSL1 5.30e-84 54.9 79 7342 45 227332 Polypharmacology Molecules Target Profile
82 ATXN2 and TUBB 3.80e-37 54.4 35 7342 20 227332 Polypharmacology Molecules Target Profile
83 ATXN2 and ADRB2 5.04e-226 54.3 213 7342 125 227332 Polypharmacology Molecules Target Profile
84 ATXN2 and HSP90AA1 9.68e-175 53.9 165 7342 97 227332 Polypharmacology Molecules Target Profile
85 ATXN2 and CASP6 3.67e-58 53.6 55 7342 32 227332 Polypharmacology Molecules Target Profile
86 ATXN2 and USP1 4.00e-76 53.6 72 7342 42 227332 Polypharmacology Molecules Target Profile
87 ATXN2 and MMP14 5.60e-56 53.3 53 7342 31 227332 Polypharmacology Molecules Target Profile
88 ATXN2 and HTR5A 1.30e-116 52.1 111 7342 67 227332 Polypharmacology Molecules Target Profile
89 ATXN2 and WHSC1 2.87e-68 52.1 65 7342 39 227332 Polypharmacology Molecules Target Profile
90 ATXN2 and VDR 7.22e-257 51.6 245 7342 152 227332 Polypharmacology Molecules Target Profile
91 ATXN2 and ATM 4.57e-24 51.0 23 7342 14 227332 Polypharmacology Molecules Target Profile
92 ATXN2 and NPBWR1 2.87e-127 50.5 122 7342 76 227332 Polypharmacology Molecules Target Profile
93 ATXN2 and S100A4 1.21e-16 49.6 16 7342 10 227332 Polypharmacology Molecules Target Profile
94 ATXN2 and UCHL5 4.57e-56 49.5 54 7342 34 227332 Polypharmacology Molecules Target Profile
95 ATXN2 and CHRM4 3.11e-197 49.5 190 7342 122 227332 Polypharmacology Molecules Target Profile
96 ATXN2 and CYP3A4 4.27e-31 49.1 30 7342 19 227332 Polypharmacology Molecules Target Profile
97 ATXN2 and ACP1 1.46e-45 48.9 44 7342 28 227332 Polypharmacology Molecules Target Profile
98 ATXN2 and STK33 3.63e-34 48.9 33 7342 21 227332 Polypharmacology Molecules Target Profile
99 ATXN2 and HTT 6.99e-213 48.6 206 7342 135 227332 Polypharmacology Molecules Target Profile
100 ATXN2 and RAD54L 4.63e-35 48.1 34 7342 22 227332 Polypharmacology Molecules Target Profile
101 ATXN2 and ITGA4 1.30e-20 47.8 20 7342 13 227332 Polypharmacology Molecules Target Profile
102 ATXN2 and NPSR1 7.12e-152 47.2 148 7342 99 227332 Polypharmacology Molecules Target Profile
103 ATXN2 and PAFAH2 1.27e-63 47.2 62 7342 41 227332 Polypharmacology Molecules Target Profile
104 ATXN2 and CXCR6 2.38e-211 47.2 206 7342 139 227332 Polypharmacology Molecules Target Profile
105 ATXN2 and CHRM5 4.90e-120 47.2 117 7342 78 227332 Polypharmacology Molecules Target Profile
106 ATXN2 and NLRP3 3.77e-49 46.7 48 7342 32 227332 Polypharmacology Molecules Target Profile
107 ATXN2 and APOBEC3F 3.77e-49 46.7 48 7342 32 227332 Polypharmacology Molecules Target Profile
108 ATXN2 and GSTO1 8.54e-165 46.7 161 7342 109 227332 Polypharmacology Molecules Target Profile
109 ATXN2 and KDM4C 3.36e-09 46.5 9 7342 6 227332 Polypharmacology Molecules Target Profile
110 ATXN2 and RACGAP1 2.26e-73 45.9 72 7342 49 227332 Polypharmacology Molecules Target Profile
111 ATXN2 and CCR6 3.98e-243 44.9 240 7342 171 227332 Polypharmacology Molecules Target Profile
112 ATXN2 and INS 2.22e-26 44.9 26 7342 18 227332 Polypharmacology Molecules Target Profile
113 ATXN2 and POLK 1.18e-53 44.7 53 7342 37 227332 Polypharmacology Molecules Target Profile
114 ATXN2 and TP53 3.06e-61 43.3 61 7342 44 227332 Polypharmacology Molecules Target Profile